Regeneron Pharmaceuticals, Inc. (REGN)

FairStock Score: 59/100 — STEADY

Key Financials

Strengths

• EYLEA franchise generates $5.8B revenue with dominant market position in wet AMD treatment
• Exceptional free cash flow of $3.3B with 21.74% net margin demonstrates operational excellence
• Conservative balance sheet with 0.10 D/E ratio and strong Altman Z-Score of 6.98
• Proprietary VelociSuite technology platform creates sustainable competitive moat in drug discovery
• Diversified pipeline across ophthalmology, oncology, immunology, and rare disease markets

Concerns

• Valuation is disconnected from reality: trading at 3.3x Graham Number with 66.45x EV/EBITDA—classic bubble territory
• EYLEA faces biosimilar competition and potential revenue erosion from pricing pressure in mature markets
• Piotroski F-Score of 6/9 indicates moderate financial quality; missing growth rate data obscures trajectory
• FCF yield of only 1.1% reflects capital intensity and limited reinvestment returns at current price levels

AI Analysis

Regeneron presents a classic biotechnology paradox—exceptional business quality undermined by speculative valuation. The company demonstrates genuine competitive advantages: EYLEA dominates ophthalmology with $5.8B in annual revenue, and their proprietary VelociSuite platform creates durable moats in drug discovery. The latest quarter's 21.74% net margin and $3.3B free cash flow generation reveal operational excellence rarely seen in biotech. However, I must sound the alarm on valuation. At $772 per share with an EV/EBITDA of 66.45x, this firm trades at roughly 3.3x the Graham Number. The P/E of 17.67 appears reasonable in isolation, yet when benchmarked against a 1.1% FCF yield and their capital intensity, the risk-reward calculus deteriorates significantly. The Piotroski F-Score of 6/9 suggests moderate financial quality—adequate but not stellar. Most troubling: the company's recent growth narrative remains opaque with missing growth rate data, while EYLEA faces biosimilar competition and pricing pressure. Their Altman Z-Score of 6.98 indicates financial stability, and leverage remains conservative at 0.10 D/E, but these strengths don't justify the premium. I see a high-quality business trading at a bubble price. I'd eagerly buy at $350-400, but at current levels, this belongs in the 'watch and wait' category. The margin of safety has evaporated.

Bull Case

Regeneron's pipeline could deliver blockbuster launches in oncology and inflammatory diseases, with EYLEA retaining pricing power longer than competitors expect. The VelociSuite platform positions them as the pharmaceutical industry's innovation leader, justifying premium multiples if new products achieve peak sales of $2B+ each.

Bear Case

EYLEA revenue declines 15-20% over five years due to biosimilar competition while pipeline fails to deliver meaningful launches. The company becomes a slow-growth, high-multiple cash cow facing multiple compression—a recipe for investor losses if biotech sentiment shifts.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer